Nasal Polyps Treatment Market Growth And Latest
Trends 2018-2026
Nasal polyps are benign growths occurring inside the paranasal sinuses and in the lining of the
nose. Generally, it is characterized as a teardrop shaped and yellowish brown or pink in color.
The size of the polyps may vary and can be clustered or may grow alone. These can cause
severe infections and breathing difficulties, causing sleep apnea in some cases. The cause of
nasal polyps can be due to asthma, allergic infections, sinus infections, cystic fibrosis, etc.
There are no particular symptoms that develop but an inflammation in the lining of the nose
can occur.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2775
Global Nasal Polyps Treatment Market Drivers
Key players are constantly focused on developing novel approaches for treatment of nasal
polyps, which is expected to impel the global nasal polyps’s treatment market growth. For
instance, in April 2018, Intersect ENT Inc. launched a product, SINUVA. It is a sinus implant
and used for treating nasal polyps. It is a new way of treatment in patients with the past sinus
surgeries. This implant contains 1.35 mg mometasone furoate which is delivered, directly to the
polyps. It is implanted for a definite period of time (90 days).
Furthermore, in June 2019, Novartis AG revealed the phase III clinical trial study of Xolair,
Omalizumab. It is a monoclonal antibody used for treating nasal polyps. It tends to target and
block the immunoglobulin E. It was observed that the medication was generally well-tolerated
in patients. Hence, such developments of treatment for nasal polyps are expected to fuel the
global nasal polyps treatment market growth.
Increasing approvals from regulatory bodies related to nasal polyps treatment is expected to
drive the global nasal polyps treatment market growth. For instance, in June 2019, Dupixent
received an approval from the U.S. Food & Drug Administration (FDA) for treating with nasal
polyps. It was manufactured by Sanofi in partnership with Regeneron Pharmaceuticals Inc. It is
the first treatment that got approved for chronic rhinosinusitis with nasal polyps. It is used
when the oral steroids are unable to control the inflammation and to avoid the surgical